Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Indole-related metabolites suppress the anti-tumor function of CD8+ T cells in the bone marrow microenvironment of multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

XJXiaoyun Jin

Discussion

Loading...

Member takes

Overview

Analysis reveals that indole-related metabolites suppress anti-tumor activity in CD8+ T cells within the bone marrow microenvironment, indicating potential therapeutic targets in multiple myeloma.

Key Points

  • Metabolomic profiling showed significant alterations in the bone marrow microenvironment, impairing CD8+ T cell function.
  • Indole-3-acetic acid and indole-3-propionic acid were noted as key immunosuppressive factors in multiple myeloma.
  • The presence of immune checkpoint molecules did not indicate a classical exhausted state in CD8+ T cells.
  • Findings emphasize the role of metabolic reprogramming in immune evasion and tumor progression in MM.

Cite This Study

Xiaoyun Jin (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5f8https://doi.org/10.1182/blood-2025-3933
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multi-omics reveals immune features in immune and non-immune cells, an IFN-γ/IFN-α-B2M positive feedback loop, and targeted metabolic therapy in multiple myeloma2025
  2. 2Multi-omics reveals immune features in immune and non-immune cells, an IFN-γ/IFN-α-B2M positive feedback loop, and targeted metabolic therapy in multiple myeloma2025
  3. 3Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma2025 · 2 citations
  4. 4Dissecting the multiple myeloma survival niche to improve novel treatment strategies2025
  5. 5An acquired immune-metabolic shift to common chemotherapy confers resistance to immunotherapies in relapsed, high-risk multiple myeloma2025